Marfan Syndrome Clinical Trial
Official title:
Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)
Marfan syndrome is a hereditary connective tissue disorder. Many individuals with this condition die because of the associated heart and blood vessel abnormalities. This study will compare the effectiveness of two medications, losartan and atenolol, at slowing aortic root enlargement in individuals with Marfan syndrome.
Marfan syndrome is an inheritable disorder that affects the body's connective tissue. An
abnormal protein results in connective tissue that is weaker than normal. Because connective
tissue is found throughout the body, Marfan syndrome can affect many body systems, including
the skeleton, eyes, nervous system, skin, lungs, heart, and blood vessels. Overall, heart
and blood vessel abnormalities are the leading cause of death in individuals with Marfan
syndrome. A common blood vessel abnormality associated with this disease involves the aorta,
which is the large artery that carries blood away from the heart to the rest of the body.
The aortic root, the portion of the aorta that is attached to the heart, may enlarge and
tear or even rupture. A tear or rupture is considered a life-threatening emergency. Recent
studies have shown that the medication losartan may reduce aortic root growth and improve
heart function. The purpose of this study is to compare the effectiveness of losartan versus
atenolol at slowing aortic root growth in individuals with Marfan syndrome.
This 3-year study will enroll individuals with Marfan syndrome. Participants will be
randomly assigned to receive either losartan or atenolol on a daily basis. All participants
will initially receive a low dose of their assigned medication. This dose will be gradually
increased every 3 to 4 weeks until the maximum tolerated dose is reached. A continuous
electrocardiogram (ECG) that monitors heart rate and activity in 24-hour intervals will be
used to determine the proper dose increase for each participant. Participants will then
receive the maximum tolerated dose for the remainder of the study. Study visits will occur
at baseline and Months 6, 12, 24, and 36. Each study visit will include a physical
examination, a medical history review, an ECG, an echocardiogram, and questionnaires.
Additionally, at the baseline study visit blood will be collected for laboratory testing.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00763893 -
Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome
|
Phase 3 | |
| Recruiting |
NCT05809323 -
Marfan Syndrome Moderate Exercise Trial II
|
N/A | |
| Completed |
NCT04776668 -
Living With Marfan Syndrome and Your Aorta
|
||
| Recruiting |
NCT01949233 -
The Oxford Marfan Trial
|
Phase 2 | |
| Active, not recruiting |
NCT01145612 -
Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome
|
Phase 3 | |
| Completed |
NCT00723801 -
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
|
Phase 3 | |
| Completed |
NCT04641325 -
Marfan Syndrome Moderate Exercise Pilot
|
N/A | |
| Recruiting |
NCT06257004 -
Genome-wide Epistasis for Cardiovascular Severity in Marfan Study
|
||
| Completed |
NCT01322165 -
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
|
N/A | |
| Recruiting |
NCT05700175 -
Transcriptomic Study of Adult Population With Marfan Syndrome
|
||
| Completed |
NCT00782327 -
Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers
|
Phase 3 | |
| Not yet recruiting |
NCT05838235 -
Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome
|
N/A | |
| Recruiting |
NCT02148900 -
Development of a Blood Test for Marfan Syndrome
|
N/A | |
| Active, not recruiting |
NCT05980104 -
Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions
|
N/A | |
| Recruiting |
NCT02050113 -
Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices
|
N/A | |
| Completed |
NCT00001641 -
Study of Heritable Connective Tissue Disorders
|
N/A | |
| Completed |
NCT01715207 -
Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol
|
Phase 3 | |
| Completed |
NCT05516043 -
Safety and Performance of POLYTHESE® Vascular Prosthesis
|
||
| Recruiting |
NCT04776681 -
Living With Marfans and Your Aorta: Surgical Outcomes Study
|
||
| Completed |
NCT03236571 -
Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome.
|
N/A |